Form 4: Silence Therapeutics Director Richard Ian Griffiths Reports Acquisition of Shares

Director Richard Ian Griffiths reports purchasing Silence Therapeutics plc shares through American Depositary Shares (ADS) on April 22 and 23, 2025.

Summary

• Richard Ian Griffiths, a director of Silence Therapeutics plc, reported acquiring shares of the company.
• The transactions occurred on April 22 and April 23, 2025.
• The acquisitions were made through American Depositary Shares (ADS).
• On April 22, 2025, 50,000 ADS were purchased at a price of $3.10.
• On April 23, 2025, another 50,000 ADS were purchased at a price of $3.18.
• Each ADS is immediately convertible into three ordinary shares.
• Following these transactions, Griffiths directly owns 10,311,299 ordinary shares.

Sentiment

Score: 6

Explanation: Director's purchase is generally a positive sign, but the impact depends on the size of the purchase relative to their existing holdings and the company's market capitalization.

Positives

• A director's purchase of shares can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Director share purchases are common and monitored by investors as an indicator of management's sentiment towards the company's valuation and future performance. This is especially relevant in the biotech industry, where clinical trial outcomes and regulatory approvals can significantly impact stock prices.

Comparison to Industry Standards

• Comparing the size of this transaction to other insider purchases in similar biotech companies would provide context on its significance.
• For example, if directors at companies like Alnylam or Ionis Pharmaceuticals made similar purchases after positive clinical trial data, it would suggest a similar level of confidence.

Stakeholder Impact

• Shareholders may view the director's purchase as a positive signal.
• The purchase could potentially increase investor confidence.

Key Dates

Keywords

Silence Therapeutics, Richard Ian Griffiths, ADS, American Depositary Shares, share acquisition, director, SLN